Newsroom

AUSTIN, Texas & IRVINE, Calif.--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN), a clinical stage biotechnology company developing immune-modulating therapies for the management and treatment of life-threatening conditions, today announced a strategic partnership to incorporate Natera’s Prospera kidney transplant assessment test into Eledon’s planned Phase 3 clinical trial of tegoprubart, an in...

NEW YORK--(BUSINESS WIRE)--OXIO, the leading Telecom-as-a-Service (TaaS) platform, today announced the launch of Advanced Core Routing (ACR), a network-native capability that gives enterprises and brands real-time, bi-directional control over mobile voice and messaging traffic through OXIO’s telecom ecosystem. A native-intercept layer built into OXIO’s cloud-native telecom core, ACR enables organizations to prevent fraud, provide custom, real-time routing and decisioning, strengthen subscriber...

CHESAPEAKE, Va.--(BUSINESS WIRE)--Dollar Tree, Inc. (NASDAQ: DLTR) (the “Company” or “Dollar Tree”) today announced that certain funds affiliated with Mantle Ridge LP (“Mantle Ridge”) and a selling stockholder that is counterparty to derivative agreements with affiliates of Mantle Ridge (collectively, the “Selling Stockholders”) have launched a secondary block trade (the “block trade”) to sell 12,820,400 shares of the Company’s common stock (the “common stock”) to J.P. Morgan and Goldman Sachs...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director. “We are pleased to welcome Jay to Insulet’s Board of Directors,” said President and CEO Ashley McEvoy. “Jay has a strong track record of...

WASHINGTON--(BUSINESS WIRE)--REPUBLICAN VOTERS SEND A CLEAR MESSAGE TO WASHINGTON: PROTECT ACCESS TO EMERGENCY CONTRACEPTION...

NEW YORK--(BUSINESS WIRE)--FlightHub, a leading North American online travel agency, is expanding its travel ecosystem with the launch of FlightHub Hotels, which will allow travelers to book flights, hotels, and bundled travel packages in one place. The new offering gives travelers access to more than 2.6 million accommodation options worldwide, marking a significant step in FlightHub’s evolution as a one-stop shop for travel planning.To celebrate the launch, FlightHub is introducing a limited-t...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced completion of patient enrollment in its Phase 2 clinical study evaluating GLK-321 for the treatment of Demodex blepharitis. GLK-321 is an investigational drug candidate using Glaukos’ proprietary iLution platform, a novel ophthalmic drug-delivery syste...

MONTREAL--(BUSINESS WIRE)--FlightHub™, a leading North American online travel agency, is expanding its travel ecosystem with the launch of FlightHub Hotels, which will allow travellers to book flights, hotels, and bundled travel packages in one place. The new offering gives travellers access to more than 2.6 million accommodation options worldwide, marking a significant step in FlightHub’s evolution as a one-stop shop for travel planning. To celebrate the launch, FlightHub is introducing a limi...

GENT, Belgien--(BUSINESS WIRE)--MRM Health, ein Biotechnologieunternehmen mit Produkten in klinischen Entwicklungsstadien, das Mikrobiom-basierte Therapeutika für immunvermittelte Erkrankungen entwickelt, gab heute die Berufung von zwei erfahrenen Branchenführern in seinen Aufsichtsrat bekannt. Die Ernennungen erfolgen zu einem bedeutenden Zeitpunkt der Unternehmensentwicklung: Nach einer erfolgreichen Serie-B-Finanzierungsrunde über 55 Millionen Euro und mit einem Wirkstoffkandidaten, MH002, i...

BALLERUP, Denmark--(BUSINESS WIRE)--LEO Pharma A/S, a global leader in medical dermatology, today announces its scientific program for the European Society of Contact Dermatitis (ESCD) Congress 2026, taking place in Copenhagen, Denmark. At the congress, hosted on LEO Pharma’s home ground, the company will present new data highlighting the burden, symptom severity and ongoing unmet needs of people living with chronic hand eczema (CHE).1-5 LEO Pharma will present multiple posters covering patient...